Total Payments
$28,449
2022 Payments
$10,750
Companies
6
Transactions
12
Medicare Patients
841
Medicare Billing
$97,641
Payment Breakdown by Category
Research$28,067 (98.7%)
Food & Beverage$232.50 (0.8%)
Education$149.62 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $28,067 | 5 | 98.7% |
| Food and Beverage | $232.50 | 2 | 0.8% |
| Education | $149.62 | 5 | 0.5% |
Payments by Type
Research
$28,067
5 transactions
General
$382.12
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $28,067 | 5 | $0 (2022) |
| Jazz Pharmaceuticals Inc. | $232.50 | 2 | $0 (2018) |
| Incyte Corporation | $99.95 | 1 | $0 (2020) |
| Amgen Inc. | $22.14 | 2 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $15.61 | 1 | $0 (2020) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $10,750 | 1 | Eli Lilly and Company ($10,750) |
| 2021 | $473.77 | 2 | Eli Lilly and Company ($461.85) |
| 2020 | $119.92 | 3 | Incyte Corporation ($99.95) |
| 2019 | $16,873 | 4 | Eli Lilly and Company ($16,851) |
| 2018 | $232.50 | 2 | Jazz Pharmaceuticals Inc. ($232.50) |
All Payment Transactions
12 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/07/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $10,750.00 | Research |
| Study: EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | ||||||
| 11/18/2021 | Eli Lilly and Company | — | — | In-kind items and services | $461.85 | Research |
| Study: EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 11/23/2020 | Eli Lilly and Company | — | — | In-kind items and services | $4.36 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | ||||||
| 02/12/2020 | Incyte Corporation | — | Education | Cash or cash equivalent | $99.95 | General |
| 01/23/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Education | In-kind items and services | $15.61 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2019 | Amgen Inc. | — | Education | In-kind items and services | $11.07 | General |
| 08/29/2019 | Amgen Inc. | — | Education | In-kind items and services | $11.07 | General |
| 08/20/2019 | Eli Lilly and Company | — | — | Cash or cash equivalent | $15,951.00 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | ||||||
| 01/28/2019 | Eli Lilly and Company | — | — | In-kind items and services | $899.92 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | ||||||
| 08/12/2018 | Jazz Pharmaceuticals Inc. | VYXEOS (Drug) | Food and Beverage | Cash or cash equivalent | $109.77 | General |
| Category: Oncology | ||||||
| 08/10/2018 | Jazz Pharmaceuticals Inc. | VYXEOS (Drug) | Food and Beverage | In-kind items and services | $122.73 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | Eli Lilly and Company | $16,855 | 3 |
| EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | Eli Lilly and Company | $11,212 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 182 | 236 | $50,977 | $19,252 |
| 2022 | 4 | 207 | 296 | $61,698 | $25,829 |
| 2021 | 4 | 206 | 300 | $63,074 | $26,275 |
| 2020 | 6 | 246 | 407 | $76,719 | $26,285 |
Total Patients
841
Total Services
1,239
Medicare Billing
$97,641
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 77 | 107 | $16,513 | $7,148 | 43.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 43 | 64 | $15,745 | $6,506 | 41.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 39 | 42 | $9,698 | $3,072 | 31.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 12 | 12 | $3,796 | $1,289 | 34.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $5,225 | $1,236 | 23.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 71 | 126 | $30,874 | $13,290 | 43.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 104 | 137 | $21,218 | $9,186 | 43.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 16 | 16 | $7,600 | $2,154 | 28.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 16 | 17 | $2,006 | $1,199 | 59.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 126 | 200 | $29,989 | $13,994 | 46.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 47 | 66 | $15,863 | $7,333 | 46.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 18 | 18 | $8,354 | $2,555 | 30.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 15 | 16 | $8,868 | $2,393 | 27.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 118 | 242 | $36,338 | $14,174 | 39.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 13 | 36 | $11,412 | $2,978 | 26.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 68 | 77 | $8,653 | $2,835 | 32.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 22 | 22 | $9,934 | $2,790 | 28.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 12 | 12 | $5,851 | $1,919 | 32.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 13 | 18 | $4,531 | $1,588 | 35.1% |
About Dr. Sarah Sinclair, DO
Dr. Sarah Sinclair, DO is a Internal Medicine healthcare provider based in Brewer, Maine. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1457399552.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sarah Sinclair, DO has received a total of $28,449 in payments from pharmaceutical and medical device companies, with $10,750 received in 2022. These payments were reported across 12 transactions from 6 companies. The most common payment nature is "" ($28,067).
As a Medicare-enrolled provider, Sinclair has provided services to 841 Medicare beneficiaries, totaling 1,239 services with total Medicare billing of $97,641. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Brewer, ME
- Active Since 06/02/2006
- Last Updated 08/16/2016
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1457399552
Products in Payments
- VYXEOS (Drug) $232.50
- KEYTRUDA (Biological) $15.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.